Chiesi advances its carbon-minimal inhaler programme with European regulatory submissions for next-generation HFA-152a pressurised metered-dose inhalers.
Chiesi has advanced its carbon-minimal inhaler programme with regulatory submissions validated in Europe for two next-generation propellant pressurised metered-dose inhalers (pMDIs).
Assessment processes are now underway in Europe for the transition of Fostair® (beclometasone / formoterol) and Trimbow® (beclometasone / formoterol / glycopyrronium) to next-generation pMDIs using the propellant hydrofluoroalkane (HFA)-152a.
The submissions follow the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) approval in July 2026 of a beclometasone pMDI formulated with HFA-152a, marking the first UK approval of a pMDI using the next-generation propellant.
The transition to HFA-152a, which Chiesi describes as a non-PFAS, low global warming potential (GWP) next-generation propellant, supports Chiesi’s ambition to achieve Net Zero by 2035 across its full value chain.
The move is intended to support the decarbonisation of respiratory care while maintaining access to pMDIs and continuity of care for patients. The transition takes Chiesi’s pMDIs away from formulations using HFA-134a to HFA-152a, which is designed to reduce the products’ carbon footprint by up to 90%.
Our focus is on delivering innovation that supports both patients and the planet – reducing environmental impact, while preserving choice and flexibility in treatment.”
-Ralph Blom, General Manager, Chiesi UK and Ireland
Speaking on the transition, General Manager of Chiesi UK and Ireland, Ralph Blom, said: “At Chiesi, our focus is on delivering innovation that supports both patients and the planet – reducing environmental impact, while preserving choice and flexibility in treatment. By evolving our portfolio in this way, we’re changing so patients don’t have to.”
Beclometasone / formoterol / glycopyrronium is being assessed by the European Medicines Agency (EMA) under an EU centralised procedure, while beclometasone / formoterol is being reviewed under a coordinated multi-country regulatory procedure, with Germany’s Federal Institute for Drugs and Medical Devices (BfArM) as the Reference Member State.
No comments yet